Organon Completes Spin-Out From Merck With Five Biosimilars
Adalimumab Recently Launched In Australia And Canada
With ambitions to continue to invest in its long-standing relationship with Samsung Bioepis, Organon has completed its spin-out from Merck & Co.
You may also be interested in...
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
Samsung Bioepis reiterated that the US pharma market is “the most fragmented and the most complicated market in the world” as it discussed its biosimilar fortunes in Europe.
Four different biosimilar versions of Humira will be listed on Australia’s PBS from the start of April, with the country’s “a-flagging” mechanism allowing substitution for the brand and between adalimumab biosimilars.